安罗替尼治疗不同部位鼻咽癌转移病灶的疗效分析

Analyzing Efficacy of Anlotinib on Nasopharyngeal Carcinoma at Different Metastatic Lesions

目的比较分析安罗替尼治疗不同部位鼻咽癌转移病灶的疗效,为优化个体化治疗提供参考。方法将单独服用安罗替尼维持治疗的鼻咽癌转移患者纳入研究,经筛选共99例。收集患者服用安罗替尼前后的CT检查结果,比较不同转移病灶的体积变化,以Recist1.1为标准计算完全缓解(CR)、部分缓解(PR)、疾病稳定(SD)、病情进展(PD)、客观缓解(ORR)、疾病控制(DCR)等患者比例。结果相对于远处器官转移,安罗替尼对于仅有颈部和咽后淋巴结出现转移的患者疗效较好,ORR为39.29%,DCR为78.57%,病灶体积得到控制的患者比例较高,颈淋巴结为78.12%,咽后淋巴结为83.33%。结论安罗替尼对于仅出现头颈淋巴结转移NPC患者疗效较好。

OBJECTIVE To compare and analyze the efficacy of anlotinib in the treatment of metastatic lesions of nasopharyngeal carcinoma in different regions,in order to provide reference for optimizing individualized treatment.METHODS Total of 99 nasopharyngeal carcinoma metastasis patients who received maintenance therapy with anlotinib alone were included in the study after being screened.CT examination results of patients before and after taking anlotinib were collected,and the volume changes of different metastatic lesions were compare.The proportion of patients with complete remission(CR),partial remission(PR),disease stability(SD),disease progression(PD),objective remission rate(ORR),and disease control rate(DCR) according to Recist 1.1 were calculated.RESULTS Compared to distant organ metastasis,anlotinib showed better therapeutic effect on patients with only neck and retropharyngeal lymph node metastasis,with ORR of 39.29% and DCR of 78.57%.The proportion of patients with controlled lesion volume was relatively high,with 78.12% of neck lymph nodes and 83.33% of retropharyngeal lymph nodes.CONCLUSION Anlotinib showed good therapeutic effect on NPC patients with only head and neck lymph node metastasis.